Technavio has announced the top six leading vendors in their recent global intracranial pressure (ICP) monitoring market report. This research report also lists 14 other prominent vendors that are expected to impact the market during the forecast period.
The global ICP monitoring market is expected to grow at a CAGR of 7.11 percent for 2015-2020.
ICP monitoring is used to measure the pressure within the skull of an individual with severe head injuries to decide the type of treatment required and to track the progression of the condition during treatment. It is a vital for individuals who are under critical care in hospitals.
“The use of non-invasive ICP monitoring for high potential applications such as pediatric and hydrocephalus is expected to improve the penetration rates worldwide. Conventional invasive ICP monitoring has limited use in pediatric and hydrocephalus applications. Also, the development of brain sensors (which can melt after the procedure) for ICP monitoring is expected to fuel the market growth, as it considerably reduces the complexities in the treatment,” says Barath Palada, a lead oncology analyst from Technavio.
Competitive Vendor Landscape
According to the report, the vendors are aggressively pursuing organic and inorganic growth strategies to improve their presence in the market. The development strategies of vendors have resulted in the technologically advanced ICP monitoring systems such as Becker External Drainage and Monitoring System, Duet External Drainage and Monitoring System, Camino ICP monitor, and NEUROVENT-PTO. All these products are invasive in nature, and involve the insertion of a catheter into the skull.
Companies are focusing on developing non-invasive ICP monitoring systems, and this is expected to shift demand toward non-invasive ICP monitoring systems. For instance, in October 2015, Vittamed raised $10 million Series A financing to facilitate the commercialization activities related to its non-invasive ICP monitoring systems.
New entrants in the market such as Third Eye Diagnostics and HeadSense Medical are expected to represent strong competition for existing players. These new companies have developed innovative non-invasive ICP monitoring systems that are expected to gain significant share during the forecast period. HeadSense Medical has developed HS-1000M monitor, which measures ICP using an Android-based tablet that includes the software, and Third Eye Diagnostics has developed Cerepress, which uses intraocular pressure as a direct proxy for ICP.
A sample report is available at: http://www.technavio.com/request-a-sample?report=52304. Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Top Six ICP Monitoring Market Vendors
Codman & Shurtleff: The company offers a wide range of monitoring systems. It has incorporated the Codman Microsensor technology in its products. It allows measuring ICP via a strain gauge microchip located at the tip of the catheter. It measures the ICP directly at the source, subdural, parenchymal or intraventricular. The data is relayed electronically rather than through a hydrostatic column or fiberoptics. It serves surgeons, operating room nurses, hospital administrators, and various healthcare professionals.
Integra LifeSciences: The company offers its products through the specialty surgical solutions segment. The segment generated a revenue of $586.9 million in FY2015 accounting for 66.48 percent of the net sales of the company in FY2015. The products manufactured by the company are used for elevated ICP, which includes TBI, SAH, and stroke. The company had introduced its Camino platform in early 2013. It is incorporated with the Camino fiber optic catheter technology, where its multi-lumen design also allows for ICP monitoring and simultaneous CSF drainage, providing an uninterrupted measurement of a proper pressure.
Medtronic: The company markets its products through its minimally invasive technologies group. This group generated a revenue of $2.38 billion in FY2015, and accounted for 11.74 percent of the net sales of the company. The company offers a range of sensors and brain monitors for this market. It incorporates bispectral index (BIS) brain monitoring technology in its products. This technology obtains raw electroencephalogram (EEG) data through specially designed BIS sensors placed on an individual’s forehead. The BIS algorithm filters, analyzes, and correlates the data collected. It also provides insights into the patient-specific effects of anesthesia on the brain to enhance perioperative outcomes.
RAUMEDIC: The company offers a range of telemetric pressure catheters that are implanted below the scalp on the cranial bone to gather ICP measurements in the parenchyma. Its products use microchip technology that facilitates the transfer of pressure value to a reader. The company would be investing $26.3 million on the development of new ICP monitors. The company distributes its products through a network of distributors internationally and in Germany, as well as through its distribution companies in selected markets.
Spiegelberg: The company develops, produces, and sells catheters and probes for neurosurgical use as well as antimicrobial products to prevent hospital-acquired infections. Its products measure ICP with the air-pouch method. Its ICP monitoring system can be used in a standalone fashion or with an ICU monitor. In FY2013, the company opened a new production unit to increase production output to meet the rising customer demand.
Vittamed: The company offers non-invasive ICP meter and cerebrovascular autoregulation monitors for individuals with post-stroke complications, concussion, hydrocephalus, stroke, brain tumors, neurological diseases, or traumatic brain injuries. The devices offered are ultrasound based. The ICP meter is clinically certified in prospective clinical trials. It allows the clinicians to monitor cerebrovascular autoregulation and assess cerebral blood flow after TBI, in stroke, during cardiac surgery, in a critical care unit, or an outpatient clinic. The non-invasive product’s diagnostic methods have been clinically tested and proven in leading neurocenters in Europe and the U.S. The company’s technology is based on the use of ultrasound probes to measure blood flows within the ophthalmic artery. The company has also undertaken projects such as TBICare and BrainCare.
Browse Related Reports:
- Neurodiagnostic and Monitoring Devices Market in the US 2016-2020
- Global Deep Brain Stimulation Market 2016-2020
- Global Neurophysiology Needles and Electrodes Market 2016-2020
Technavio is a leading global technology research and advisory company. The company develops over 2,000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
(Source: Business Wire)